# US 8,784,773 B2 · Hydrogel nanocomposite wound dressing and a method of synthesizing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,773 B2
- Document ID: US8784773B2
- Status: Granted
- Kind: B2
- Application number: 13/405,243
- Filed: 2012-02-25
- Published: 2013-08-29
- Granted: 2014-07-22
- Earliest claimed: 2012-02-25
- Applicants: Mohammad Mojmeli Renani; Mehran Solati Hashjin; Mohammad Rabiee; Yasaman Ganji; Leila Parsa; Masoomeh Mojmeli Renani
- Inventors: Mohammad Mojmeli Renani; Mehran Solati Hashjin; Mohammad Rabiee; Yasaman Ganji; Leila Parsa; Masoomeh Mojmeli Renani
- Web page: https://patentgrep.com/patent/US8784773B2

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61F 5/44: Devices worn by the patient for reception of urine, faeces, catamenial or other discharge (absorbent pads, e.g. sanitary towels, A61F13/15; drainage appliances for wounds A61M27/00); Colostomy devices
- A61F 13/00: Bandages or dressings (radioactive dressings {A61N5/1029}); Absorbent pads
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61P 31/04: Antibacterial agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- Y10S 977/775: Nanosized powder or flake, e.g. nanosized catalyst
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The various embodiments herein provide hydrogel nanocomposite wound dressing comprising a polymeric basal matrix, a reinforcing agent, a biological sensor and an antibiotic for a slow release in a wound when applied. The polymeric basal matrix is made up of polyvinyl alcohol polymer with an amount of 1-15% by weight. The reinforcing agent comprises clay nanoparticles to inhibit a sudden drug release. The clay nanoparticles comprise montmorillonite nano particles with an amount of 0-2% by weight. The biological sensor is a peptide chain. The peptide chain is thrombin sensitive with an amount from 50 to 200 mg. The antibiotic is gentamycine with an amount of 1-3% by weight. The embodiments herein also provide a method of synthesizing the hydrogel nanocomposite wound dressing.

## Claims

### Claim 1

A hydrogel nanocomposite wound dressing comprising:
a polymeric basal matrix, wherein the polymeric basal matrix is made up of polyvinyl alcohol polymer with an amount of 1-15% by weight;
a reinforcing agent, wherein the reinforcing agent comprises clay nanoparticles to inhibit a sudden drug release, wherein the clay nanoparticles comprises montmorillonite nano particles with an amount of 0-2% by weight;
a biological sensor, wherein the biological sensor is a peptide chain, wherein the peptide chain is thrombin sensitive with a presence amount of 50 to 200 mg, and the peptide chain is Gly-(D)Phe-Pro-Arg-Gly-Phe-Ala-Gly-Gly; and
an antibiotic with an amount of 1-3% by weight, and wherein the antibiotic is slowly released in a wound.

### Claim 2 (depends on 1)

The wound dressing according to claim 1, wherein the polyvinyl alcohol polymer has a degree of polymerization of 1700.

### Claim 3 (depends on 1)

The wound dressing according to claim 1, wherein the polyvinyl alcohol polymer has a molecular weight of 26300-30000.

### Claim 4 (depends on 1)

The wound dressing according to claim 1, wherein the montmorillonite nano particles have a saponification value of greater than 98%.

### Claim 5 (depends on 1)

The wound dressing according to claim 1, wherein the montmorillonite nanoparticles are both modified and non-modified montmorillonite nanoparticles.

### Claim 6 (depends on 1)

The wound dressing according to claim 1, wherein the modified and non modified montmorillonite nanoparticles have a particle size of about 2 nm.

### Claim 7 (depends on 1)

The wound dressing according to claim 1, wherein the antibiotic is gentamycine.

### Claim 8 (depends on 1)

The wound dressing according to claim 1, wherein the hydrogel nanocomposite wound dressing is transparent.

### Claim 9 (depends on 1)

The wound dressing according to claim 1, wherein the antibiotic is released in 20 hours and reaches to a maximum level in first 2 hours, and wherein the antibiotic is released after a breaking down of the peptide chain.

### Claim 10 (depends on 1)

The wound dressing according to claim 1, wherein the hydrogel nanocomposite wound dressing is infection absorbent and prevents from infection in non-infectious wounds by preventing a microbial permeation and wherein the hydrogel nanocomposite wound dressing is non-toxic.

### Claim 11 (depends on 1)

The wound dressing according to claim 1, wherein the hydrogel nanocomposite wound dressing treats infectious wound without a need for a repetitive replacement.

### Claim 12

A method of synthesizing a hydrogel nanocomposite wound dressing comprises:
carboxylating a Polyvinyl alcohol nanocomposite hydrogel structure;
linking a peptide chain with the carboxylated PVA nanocomposite hydrogel structure; and
linking an antibiotic with a peptide chain, wherein the antibiotic is gentamycin and wherein the peptide chain is Gly-(D)Phe-Pro-Arg-Gly-Phe-Ala-Gly-Gly.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the step of carboxylating a PVA nanocomposite hydrogel structure includes:
preparing aqueous solutions of Polyvinyl alcohol (PVA) with a percentage of 1-15% and a clay with a percentage of 1-10%;
providing a thermal treatment process to the prepared aqueous solutions of the PVA and the clay, wherein the thermal treatment process involves a heating and a cooling of the solutions, wherein the heating involves heating the prepared aqueous solutions of the PVA and the clay at +20° C. for 24 hours and wherein the cooling involves cooling the prepared aqueous solutions of the PVA and the clay at −20° C. for 24 hours, wherein the process is performed twice;
carboxylating the thermally treated solution by adding dimethyl sulfoxide;
adding succinic anhydride and pyridine to the thermally treated solution added with dimethyl sulfoxide;
holding the thermally treated solution added with dimethyl sulfoxide, succinic anhydride and pyridine at 10° C. for an overnight to complete the carboxylation reaction;
extracting a resultant hydrogel;
washing the extracted resultant hydrogel with Phosphate Buffer Saline (PBS) to obtain a first resultant solution;
washing the first resultant solution with Distilled Deionized Water (DDW) for several times to obtain a second resultant solution;
washing the second resultant solution with dimethyl formamide for several times to remove unreacted materials.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the step of linking a peptide chain with the carboxylated PVA nanocomposite hydrogel structure includes:
holding the washed carboxylated PVA nanocomposite hydrogel with a solution of formamide having a volume of 10 cc to obtain a sample, wherein the solution of formamide contains 50 mg of N-Hydroxysuccinimide (HOSU) and 80 mg of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC);
placing the sample in a solution of peptide chain with an amount of 120 mg for an overnight; and
washing the sample placed in a solution of peptide chain with PBS for several times to remove all remaining unreacted materials.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the step of linking the gentamycine with the peptide chain includes mechanically stirring a solution of linked peptide with carboxylated PVA nanocomposite hydrogel for 24 hours in a solution comprising gentamycin with an amount of 7 g and EDC with an amount of 25 mg.